Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo.

The cell differentiation potential of 13-cis retinoic acid (RA) has not succeeded in the clinical treatment of glioblastoma (GBM) so far. However, RA may also induce the expression of resistance genes such as HOXB7 which can be suppressed by Thalidomide (THAL). Therefore, we tested if combined treatment with RA+THAL may inhibit growth of glioblastoma in vivo. Treatment with RA+THAL but not RA or THAL alone significantly inhibited tumour growth. The synergistic effect of RA and THAL was corroborated by the effect on proliferation of glioblastoma cell lines in vitro. HOXB7 was not upregulated but microarray analysis validated by real-time PCR identified four potential resistance genes (IL-8, HILDPA, IGFBPA, and ANGPTL4) whose upregulation by RA was suppressed by THAL. Furthermore, genes coding for small nucleolar RNAs (snoRNA) were identified as a target for RA for the first time, and their upregulation was maintained after combined treatment. Pathway analysis showed upregulation of the Ribosome pathway and downregulation of pathways associated with proliferation and inflammation. In conclusion, combined treatment with RA + THAL delayed growth of GBM xenografts and suppressed putative resistance genes associated with hypoxia and angiogenesis. This encourages further pre-clinical and clinical studies of this drug combination in GBM.

[1]  K. Aldape,et al.  Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. , 2015, Neuro-oncology.

[2]  J. D. de Groot,et al.  Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects , 2014, Clinical Cancer Research.

[3]  P. Kondaiah,et al.  STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma. , 2014, Journal of neurosurgery.

[4]  S. Ryu,et al.  Proteomic analysis of hypoxia‐induced U373MG glioma secretome reveals novel hypoxia‐dependent migration factors , 2014, Proteomics.

[5]  J. Y. Kim,et al.  HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines , 2014, Genes & cancer.

[6]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[7]  F. Wenz,et al.  The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells. , 2014, Anticancer research.

[8]  R. Wu,et al.  Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma , 2014, Genes & cancer.

[9]  T. Cloughesy,et al.  Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.

[10]  F. Wenz,et al.  Mitogenic signalling in the absence of epidermal growth factor receptor activation in a human glioblastoma cell line , 2013, Journal of Neuro-Oncology.

[11]  R. Baxter,et al.  TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells , 2013, Molecular and Cellular Endocrinology.

[12]  Y. Kodera,et al.  Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma , 2013, Molecular Cancer.

[13]  Pengcheng Zhu,et al.  Emerging Roles of Angiopoietin-like 4 in Human Cancer , 2012, Molecular Cancer Research.

[14]  P. Dollé,et al.  Retinoic acid signalling during development , 2012, Development.

[15]  J. L. Ding,et al.  Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors. , 2011, Cancer cell.

[16]  K. Thennarasu,et al.  Grade-Specific Expression of Insulin-like Growth Factor–Binding Proteins-2, -3, and -5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[17]  B. Montanini,et al.  Eukaryotic snoRNAs: a paradigm for gene expression flexibility. , 2009, Genomics.

[18]  G. Duester.  Retinoic Acid Synthesis and Signaling during Early Organogenesis , 2008, Cell.

[19]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Lohr,et al.  Inhibition of 13-cis retinoic acid-induced gene expression of homeobox B7 by thalidomide , 2007 .

[21]  C. Chomienne,et al.  Epigenetic patterns of the retinoic acid receptor β2 promoter in retinoic acid-resistant thyroid cancer cells , 2007, Oncogene.

[22]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[23]  M. Blagosklonny.  How avastin potentiates chemotherapeutic drugs: Action and reaction in antiangiogenic therapy , 2005, Cancer biology & therapy.

[24]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Yusuke Nakamura,et al.  Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. , 2005, Cancer research.

[26]  Erwin G. Van Meir,et al.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.

[27]  Susan M. Chang,et al.  A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. , 2005, International journal of radiation oncology, biology, physics.

[28]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[29]  Susan M. Chang,et al.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[30]  K. Hess,et al.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[31]  Erwin G. Van Meir,et al.  Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.

[32]  Kuender D Yang,et al.  Induction of Interleukin-8 Expression in Neuroblastoma Cells by Retinoic Acid: Implication of Leukocyte Chemotaxis and Activation , 1993, Pediatric Research.

[33]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[34]  W. Yung,et al.  Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. , 1989, Cancer research.

[35]  S. D. de Armond,et al.  Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line , 1988, International journal of cancer.

[36]  N. Sidell,et al.  Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. , 1982, Journal of the National Cancer Institute.

[37]  Peter Vaupel,et al.  Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. , 2014, Advances in experimental medicine and biology.

[38]  N. Banik,et al.  Molecular Mechanisms of the Combination of Retinoid and Interferon-gamma for Inducing Differentiation and Increasing Apoptosis in Human Glioblastoma T98G and U87MG Cells , 2008, Neurochemical Research.

[39]  A. Koong,et al.  Epigenetic Regulation of Gene Expression in Cervical Cancer Cells by the Tumor Microenvironment 1 , 2000 .